WO2001017370A1 - Nutritional compositions - Google Patents
Nutritional compositions Download PDFInfo
- Publication number
- WO2001017370A1 WO2001017370A1 PCT/GB2000/003452 GB0003452W WO0117370A1 WO 2001017370 A1 WO2001017370 A1 WO 2001017370A1 GB 0003452 W GB0003452 W GB 0003452W WO 0117370 A1 WO0117370 A1 WO 0117370A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trehalose
- composition
- food product
- weight
- individual
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 95
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 94
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 93
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 74
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000008103 glucose Substances 0.000 claims abstract description 59
- 102000004877 Insulin Human genes 0.000 claims abstract description 34
- 108090001061 Insulin Proteins 0.000 claims abstract description 34
- 229940125396 insulin Drugs 0.000 claims abstract description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000004060 metabolic process Effects 0.000 claims abstract description 16
- 235000013361 beverage Nutrition 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 230000035764 nutrition Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 235000021485 packed food Nutrition 0.000 claims abstract description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims description 26
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- 235000009508 confectionery Nutrition 0.000 claims description 12
- 235000003599 food sweetener Nutrition 0.000 claims description 10
- 239000003765 sweetening agent Substances 0.000 claims description 10
- 235000015895 biscuits Nutrition 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- 235000013325 dietary fiber Nutrition 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 235000019219 chocolate Nutrition 0.000 claims description 5
- 235000014214 soft drink Nutrition 0.000 claims description 5
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 235000011962 puddings Nutrition 0.000 claims description 3
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 235000015067 sauces Nutrition 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000021185 dessert Nutrition 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 235000000346 sugar Nutrition 0.000 abstract description 7
- 230000006362 insulin response pathway Effects 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 229940068196 placebo Drugs 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- 244000299461 Theobroma cacao Species 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000008960 ketchup Nutrition 0.000 description 4
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000019220 whole milk chocolate Nutrition 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 244000307700 Fragaria vesca Species 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 108010087472 Trehalase Proteins 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000021074 carbohydrate intake Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- QEWLHSNMEXFSCI-UHFFFAOYSA-N Alloclamide hydrochloride Chemical compound Cl.CCN(CC)CCNC(=O)C1=CC=C(Cl)C=C1OCC=C QEWLHSNMEXFSCI-UHFFFAOYSA-N 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000021430 malt vinegar Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009064 short-term regulation Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/181—Sugars or sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/346—Finished or semi-finished products in the form of powders, paste or liquids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/60—Salad dressings; Mayonnaise; Ketchup
- A23L27/63—Ketchup
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/06—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing beet sugar or cane sugar if specifically mentioned or containing other carbohydrates, e.g. starches, gums, alcohol sugar, polysaccharides, dextrin or containing high or low amount of carbohydrate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the use of compositions comprising trehalose for the nutrition of persons suffering from medical disorders mediated by insulin metabolism, such as diabetic persons. It also relates to the use of trehalose for the preparations of compositions for use in the treatment or prevention of such disorders.
- the short term regulation of blood glucose levels after meals or during the first few hours of starvation is mainly determined by the release of the hormones insulin or glucagon into the blood stream.
- the initial high blood glucose levels after consuming carbohydrate-rich foods can often be followed by low blood glucose levels as the released insulin overcompensates, an effect known as a hypoglycaemic dip.
- Type I diabetes is caused by a lack of insulin as a result of damage to the B-cells of the pancreas and is treated with insulin administered by injection.
- Type II diabetes commonly occurs with age and includes defects in the ability of the B-cells to respond to increased glucose concentrations or decreased sensitivity of target cells to normal insulin levels. It has been hypothesised that controlling the incidence of insulin release might reduce the risk or postpone the onset of Type II diabetes.
- Type III diabetes occurs during pregnancy.
- Trehalose ⁇ -D-glucopyranosyl- ⁇ -D-glucopyranoside
- trehalose is, in fact, rapidly absorbed by the body.
- the mechanism of absorption is that trehalase enzyme in the microvilli of the small intestine breaks the trehalose down into its constituent glucose monomers, which are then absorbed through the intestinal wall.
- WO96/08979 describes isotonic or hypotonic sports beverages containing trehalose.
- the sports beverages containing trehalose are said to be useful for providing a quick energy boost by restoring blood glucose levels of athletes.
- the use of trehalose rather than glucose is said to be desirable because of the lower osmotic pressure of a given weight concentration of a disaccharide such as trehalose compared to a monosaccharide such as glucose.
- the sports beverages would be suitable for nutrition of diabetics.
- EP-A-0619951 also describes energy supplements containing trehalose. Data are presented showing that relatively small orally administered doses of trehalose (apparently less than 0.01 g/kg of the body weight) boost blood glucose levels slightly more slowly than corresponding doses of pure glucose. It was also found that the trehalose gives a slightly smaller, but still substantial, insulin response than the equivalent amount of glucose. There is no suggestion in this reference to use trehalose in diabetic foodstuffs, and indeed the teaching of the reference suggests that trehalose should be used to achieve a quick boost in blood glucose levels. The reduction in insulin response of trehalose relative to glucose reported in this reference is insubstantial, and would not lead the skilled person to consider trehalose as a diabetic foodstuff.
- EP-A-0693558 and EP-A-0850947 describe sweetener compositions comprising crystalline trehalose in combination with an intense sweetener such as ASPARTAME (Registered Trade Mark).
- the sweetener compositions are said to be useful as low-calorie sweeteners to sweeten foods for persons with diabetes or obesity. This can only be the case if the sweetener is used to replace a larger amount of sucrose in order to achieve a desired sweetness in a product.
- Tehalose itself is not a low calorie sweetener, since it is metabolised in the body and is less sweet than sucrose). In other words, these sweetener compositions must be substantially more sweet than sucrose, and must be used in substantially smaller amounts than sucrose, in order to achieve the stated advantages.
- CN-A-1154214 describes proteinaceous foodstuffs containing 36-42% of protein, 8-10% of dietary fiber and 5 to 8% by weight of trehalose.
- the foodstuffs are said to be useful as diabetic foods. Consumption of normal amounts of these foodstuffs would result in relatively low doses of trehalose. Furthermore, this level of dietary fiber would be expected to reduce significantly the digestion of trehalose.
- the present inventors have found that larger doses of orally administered trehalose behave very differently from the small doses described in the above documents. Larger doses of trehalose are absorbed more slowly, and provoke a very much smaller insulin response in healthy subjects than corresponding oral doses of glucose. The reasons for this behaviour are not clear, but it may be due to a limiting rate for trehalose breakdown and transport in the small intestine. In any case, it leads to the surprising conclusion that trehalose may be especially suitable for the nutrition of diabetics and other persons suffering from disorders of insulin metabolism. Accordingly, the present invention provides a method of nutrition of a person suffering from a disorder of insulin metabolism comprising the step of oral administration of a composition comprising trehalose in an amount of at least 0.1 grams of trehalose per kilogram body weight of said person.
- the present invention also provides the use of trehalose for the preparation of an edible composition for use in a method of treatment or prevention of disorders due to defective insulin metabolism comprising administration of the edible composition according to the method of the present invention.
- the treatment referred to is not primarily curative, but rather is directed to reduction of the adverse effects that can arise from conventional nutrition of a person suffering from such a disorder by substitution of the trehalose composition for e.g a sucrose composition.
- the preventive use of trehalose according to the present invention is envisaged because it is thought that the use of trehalose in nutrition instead of conventional sugars such as sucrose may reduce the incidence of disorders of insulin metabolism in persons predisposed to such disorders.
- Such preventive use of trehalose is more a matter of dietary management performed by healthy individuals rather than active medical prophylaxis.
- the disorder mediated by insulin metabolism may, for example, be diabetes (Type I or Type II) or hyperinsulinaemia. Conditions leading to increased risk of defects in insulin metabolism include obesity, heart problems, stroke, or physical trauma or disease of organs involved in insulin metabolism.
- the disorder includes diabetes.
- the use of trehalose according to the present invention may be especially useful for the prophylaxis of Type II diabetes.
- the nutritional composition comprises at least 10% by weight of trehalose, more preferably at least 20% by weight of trehalose, still more preferably at least 30% by weight, and most preferably at least 40 or 50% by weight of trehalose based on the total weight of dry substance in the composition.
- the composition comprises less than 8% by weight of dietary fiber, more preferably less than 5% by weight of dietary fiber, and most preferably less than 2% by weight of dietary fiber.
- the composition is selected from the group consisting of chocolate, hard sweets, biscuits, fondants, jellies, jams, sauces, puddings, syrups, soft drinks, sweet or savoury snack foods, cakes and other baked goods, ice cream, and combinations thereof.
- the composition may further comprise an intense sweetener such as saccharin or aspartame to bring the sweetness of the composition up to the level of an equivalent composition made with sucrose.
- the total sweeteners in the composition preerably have a combined sweetness less than 1.5 times the sweetness of sucrose, more preferably less than 1.2 times the sweetness of sucrose. This enables the sweeteners, consisting mainly of trehalose, to fulfil the calorific and other (e.g. bulking and humectant) roles of sucrose in conventional foodstuffs.
- Trehalose has been found to produce more acceptable diabetic or dietetic food products, for example with improved organoleptic properties or the lack of unpleasant gastro-intestinal effects associated with some carbohydrates such as fructose or sorbitol commonly used in such foods.
- the step of oral administration comprises administration of at least 0.1g of trehalose per kg body weight of the diabetic person, preferably at least 0.3 g/kg, more preferably at least 0.5g/kg, and most preferably at least 0.7 g/kg.
- the benefits of trehalose use in accordance with the present invention are especially notable at the higher doses.
- the present invention also provides a diabetic packaged food product or beverage for individual consumption comprising at least 10 grams of trehalose.
- the food product is portioned, and preferably individually packaged, for consumption of the whole food product portion by one person substantially at one time.
- Examples include confectionery products such as candy bars, individual ice creams, individual baked products such as individual cakes, individual soft drinks such as cans of carbonated beverages, or individual desserts such as individual puddings, jellies, mousses or milk based desserts.
- the individual food product contains at least 20g of trehalose, more preferably at least 30g of trehalose, still more preferably at least 40 g of trehalose, and most preferably at least 50g of trehalose.
- the individual food product weighs from 20 to 250 grams, more preferably from 40 to 150 grams.
- the individual beverage volume is from 150 to 1000 ml, more preferably from 200 to 750 ml.
- Candy bars weighing 40 to 100g and soft drink cartons, cans or bottles having volumes of 250 to 550ml are especially preferred.
- the weight concentration of trehalose in the food product is at least 25% based on the weight of the food product excluding packaging.
- the concentration of trehalose in the beverage is at least 100mg/ml.
- the trehalose in the packaged food products according to this aspect of the invention preferably substantially replaces the sucrose and other sugars such as maltose and glucose that are unsuitable for consumption by diabetics.
- the food product or beverage comprises less sucrose than trehalose, and more preferably the food product comprises less than 10 g of sucrose, glucose or maltose.
- the food product comprises less than 10% by weight of sucrose plus glucose plus maltose, and the beverage comprises less than 50 mg/ml of sucrose plus glucose plus maltose.
- the packaged food products or beverages according to this aspect of the invention may contain added sweeteners such as ASPARTAME (Registered Trade Mark).
- ASPARTAME Registered Trade Mark
- the food products or beverages are not low calorie products.
- the food products have a calorie content of at least 1 kcal/g, more preferably at least 2 kcal/g, and still more preferably at least 3 kcal/g.
- the beverages have a calorie content of at least 0.2 kcal/ml, more preferably at least 0.3 kcal/ml and most preferably at least 0.4 kcal/ml.
- Figure 1 shows the effect of ingesting 5% and 10% aqueous trehalose solutions on plasma glucose concentration of healthy (non-diabetic) subjects. Data are also shown for a placebo and for a comparative 5% glucose aqueous solution;
- Figure 2 shows the effect of ingesting the same beverages as in Figure 1 on plasma insulin concentration of healthy (non-diabetic) subjects.
- the glucose solution contained 5% w/v glucose and two trehalose solutions were used containing 5 and 10% w/v trehalose.
- the mean fluid intakes were 1036 ⁇ 104 ml for the placebo (PLA), glucose (GLU) and 5% trehalose (T5) drinks and 518 ⁇ 52 ml for the 10% trehalose (T10) drink.
- the mean sugar intakes were 51.8 ⁇ 5.2 g for the glucose and trehalose treatments.
- the osmolality of the drinks was measured using a freezing point osmometer (Advanced Instruments) and was 110, 361 , 255 and 386 mOsm/kg for the PLA, GLU, T5 and T10 drinks, respectively (note that 80 mOsm/kg of each drink was attributable to the added trisodium citrate).
- the order of the treatments was randomised and blinded to the subjects. The subjects remained seated throughout the 3 hours. During each test the subjects were asked about the palatability of the drinks and they were also asked to report any gastrointestinal discomfort experienced during and following the tests.
- Blood samples were obtained before consumption of the drink and at 5, 10 and 15 minutes after consumption of the drink. Further blood samples were obtained at 15 minute intervals for up to 3 hours after consumption of the drink. About 5 ml of blood was placed into heparinised tubes. An aliquot was used to determine haemoglobin concentration and haematocrit so that plasma volume changes could be estimated according to Dill and Costill J. Appl. Phvsiol. Vol 37, pages 247-248 (1974). The remainder of the blood was centrifuged at 1500 g at 4°C to obtain plasma.
- the latter was stored at -70°C prior to analysis for glucose using an enzymatic, spectrophotometric method (Sigma Chemicals kit HK-20), insulin (by radioimmunoassay using an ICN Biomedicals insulin antibody coated tube kit) and total protein (Biuret method, with bovine serum albumin as standard) concentrations.
- the coefficient of variation for the assays was ⁇ 1.9% for glucose, ⁇ 0.5% for protein and ⁇ 3.0% for insulin.
- the mean resting plasma glucose concentration before consumption of the drinks was 5.1 mmo1/1.
- the change in plasma glucose concentration following consumption of the different drinks is shown in Figure 1.
- On the PLA treatment the plasma glucose concentration remained stable throughout the 3 hour period. Following GLU ingestion, plasma glucose concentration rose significantly after 10 minutes and reached a peak of 7.64 ⁇ 0.57 mmo1/l alter 32 ⁇ 2 minutes and had returned to normal by 45-60 minutes. After 90-120 minutes the plasma glucose concentration fell to a minimum of 3.59 ⁇ 0.21 mmol/l; at this point the plasma glucose concentration was significantly lower than that observed on the T5 trial.
- Plasma protein concentration fell on average by 7% during the tests (P ⁇ 0.0l) but there were no significant differences between the treatments.
- the mean resting plasma insulin concentration before consumption of the drinks was 18 mU/l.
- the change in plasma insulin concentration following consumption of the different drinks is shown in Figure 2.
- the plasma insulin concentration remained stable throughout the 3 hour period.
- plasma insulin concentration increased and reached a peak of 92 ⁇ 31 mU/l after 30 minutes and had returned to normal by 90-120 minutes.
- trehalose has a glycaemic index that is on average a little lower that that of glucose, but is still medium-high. There was, however, a wide variation between different individuals. Those subjects who had a large AUC60 on T5 also showed a large response on T10, which suggests that interindividual differences in gut trehalase activity may be responsible for this large degree of variation.
- Plasma glucose concentration was maintained at or above basal (placebo) levels for longer with T10 compared with GLU, and there was no significant reactive hypoglycaemia with T5 or T10, whereas this was noticeable 90-120 minutes after GLU ingestion. This is likely to be due to the substantially larger peak insulin response following GLU ingestion compared with the trehalose drinks.
- Example 2 5 Foodstuffs in accordance with the present invention are prepared as follows:
- the hard candy was prepared in accordance with the following instructions:
- a milk chocolate was formulated as follows:-
- the chocolate was made with conventional chocolate processing machinery in accordance with the following instructions:
- the trehalose was milled to 50 ⁇ m.
- Kneading Add all the ingredients except the lecithin and enough cocoa butter to provide a suitable consistency for the roller refining operation.
- the chocolate was tempered with the same conditions as for standard milk chocolate (40°C-27°C-30°C) then moulded up.
- a tomato ketchup was formulated as follows:-
- Tomato Ketchup Spice LID-SM986 0.2 The tomato ketchup was prepared in accordance with the following instructions:- 1. Weigh out all ingredients except water and starch into pan. 2. Disperse starch in water then add to pan.
- the biscuits were formulated as follows:-
- the biscuits were prepared in accordance with the following instructions:- 1. Mix fat and sugar. 2. Dissolve salt in the water an
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70253/00A AU7025300A (en) | 1999-09-09 | 2000-09-08 | Nutritional compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9921336A GB2353934A (en) | 1999-09-09 | 1999-09-09 | Nutritional compositions comprising trehalose for persons suffering from diabetes |
GB9921336.5 | 1999-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001017370A1 true WO2001017370A1 (en) | 2001-03-15 |
Family
ID=10860648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003452 WO2001017370A1 (en) | 1999-09-09 | 2000-09-08 | Nutritional compositions |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7025300A (en) |
GB (1) | GB2353934A (en) |
WO (1) | WO2001017370A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890571B2 (en) | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
US6929817B2 (en) | 2002-05-14 | 2005-08-16 | National Starch & Chemical Investment Holding Corporation | Slowly digestible starch product |
US7081261B2 (en) * | 2002-05-14 | 2006-07-25 | National Starch And Chemical Investment Holding Corporation | Resistant starch prepared by isoamylase debranching of low amylose starch |
WO2007073187A1 (en) * | 2005-12-20 | 2007-06-28 | N.V. Nutricia | Carbohydrate composition for flat glucose response |
WO2012013975A1 (en) | 2010-07-27 | 2012-02-02 | Omniceutica Limited | Nutritional compositions |
US9095157B2 (en) | 2006-11-09 | 2015-08-04 | Toms Gruppen A/S | Sweet confectionery products |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
WO2004084655A1 (en) * | 2003-03-24 | 2004-10-07 | Cerestar Holding B.V. | Comestibles containing isomaltulose and trehalose for sustained carbohydrate energy release and reduced glycemic/insulinemic responses, and for preserving osmolality |
US8231925B2 (en) | 2004-08-20 | 2012-07-31 | Cargill, Incorporated | Ingredient systems comprising trehalose, food products containing trehalose, and methods of making same |
EP1791443A1 (en) | 2004-08-20 | 2007-06-06 | Cargill, Incorporated | Ingredient systems comprising trehalose, food products containing trehalose, and methods of making same |
CN104840455A (en) | 2005-02-24 | 2015-08-19 | 扩散药品有限公司 | Trans carotenoids, their synthesis, formulation and uses |
EP2146948A4 (en) | 2007-04-13 | 2010-08-04 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
MX2010004803A (en) * | 2007-10-31 | 2010-09-09 | Diffusion Pharmaceuticals Llc | A new class of therapeutics that enhance small molecule diffusion. |
EP2445339B1 (en) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
JP5869882B2 (en) * | 2010-03-05 | 2016-02-24 | 株式会社林原 | Insulin resistance prevention and / or improvement agent |
CN103124498A (en) | 2010-06-02 | 2013-05-29 | 扩散药品有限公司 | Oral formulations of bipolar trans carotenoids |
KR102489034B1 (en) | 2016-03-24 | 2023-01-13 | 디퓨젼 파마슈티컬즈 엘엘씨 | Use of Bipolar Trans Carotenoids with Chemotherapy and Radiation Therapy to Treat Cancer |
IT201900001763A1 (en) * | 2019-02-07 | 2020-08-07 | Loris Ballarin | SEMI-FINISHED PRODUCT FOR THE PREPARATION OF ICE CREAM WITH A LOW GLYCEMIC INDEX AND A REDUCED CALORIC CONTENT |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62257346A (en) * | 1986-04-30 | 1987-11-09 | Lotte Co Ltd | Preparation of fondant-like sugar candy from palatinose |
EP0297887A1 (en) * | 1987-06-29 | 1989-01-04 | Quadrant Bioresources Limited | Food process |
EP0622025A2 (en) * | 1993-04-28 | 1994-11-02 | Ajinomoto Co., Inc. | Sweet ice stuffs and jellied foods |
EP0688501A1 (en) * | 1994-05-31 | 1995-12-27 | Ajinomoto Co., Inc. | Method for producing bread |
EP0693558A1 (en) * | 1994-07-19 | 1996-01-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Trehalose and its production and use |
EP0797999A2 (en) * | 1996-03-26 | 1997-10-01 | Eli Lilly And Company | Formulations of obesity protein |
EP0834516A1 (en) * | 1996-10-07 | 1998-04-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | High trehalose content syrup |
WO1999026485A1 (en) * | 1997-11-21 | 1999-06-03 | Wm. Wrigley Jr. Company | Chewing gum containing trehalose |
JPH11158075A (en) * | 1997-11-25 | 1999-06-15 | Hayashibara Biochem Lab Inc | Pancreatic function regulator |
JP2000007570A (en) * | 1998-06-24 | 2000-01-11 | Hayashibara Biochem Lab Inc | Anti-endocrinosis agent |
GB2339197A (en) * | 1998-07-09 | 2000-01-19 | Hayashibara Biochem Lab | Crystalline trehalose dihydrate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4034846B2 (en) * | 1996-12-10 | 2008-01-16 | 株式会社林原生物化学研究所 | Crystalline powdered sugar, production method and use thereof |
-
1999
- 1999-09-09 GB GB9921336A patent/GB2353934A/en not_active Withdrawn
-
2000
- 2000-09-08 WO PCT/GB2000/003452 patent/WO2001017370A1/en active Search and Examination
- 2000-09-08 AU AU70253/00A patent/AU7025300A/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62257346A (en) * | 1986-04-30 | 1987-11-09 | Lotte Co Ltd | Preparation of fondant-like sugar candy from palatinose |
EP0297887A1 (en) * | 1987-06-29 | 1989-01-04 | Quadrant Bioresources Limited | Food process |
EP0622025A2 (en) * | 1993-04-28 | 1994-11-02 | Ajinomoto Co., Inc. | Sweet ice stuffs and jellied foods |
EP0688501A1 (en) * | 1994-05-31 | 1995-12-27 | Ajinomoto Co., Inc. | Method for producing bread |
EP0693558A1 (en) * | 1994-07-19 | 1996-01-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Trehalose and its production and use |
EP0797999A2 (en) * | 1996-03-26 | 1997-10-01 | Eli Lilly And Company | Formulations of obesity protein |
EP0834516A1 (en) * | 1996-10-07 | 1998-04-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | High trehalose content syrup |
WO1999026485A1 (en) * | 1997-11-21 | 1999-06-03 | Wm. Wrigley Jr. Company | Chewing gum containing trehalose |
JPH11158075A (en) * | 1997-11-25 | 1999-06-15 | Hayashibara Biochem Lab Inc | Pancreatic function regulator |
JP2000007570A (en) * | 1998-06-24 | 2000-01-11 | Hayashibara Biochem Lab Inc | Anti-endocrinosis agent |
GB2339197A (en) * | 1998-07-09 | 2000-01-19 | Hayashibara Biochem Lab | Crystalline trehalose dihydrate |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Section Ch Week 200018, Derwent World Patents Index; Class B03, AN 2000-199606, XP002153212 * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 139 (C - 491) 27 April 1988 (1988-04-27) * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 11 30 September 1999 (1999-09-30) * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890571B2 (en) | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
US6929817B2 (en) | 2002-05-14 | 2005-08-16 | National Starch & Chemical Investment Holding Corporation | Slowly digestible starch product |
US7081261B2 (en) * | 2002-05-14 | 2006-07-25 | National Starch And Chemical Investment Holding Corporation | Resistant starch prepared by isoamylase debranching of low amylose starch |
AU2003204157B2 (en) * | 2002-05-14 | 2007-08-30 | Brunob Ii B.V. | Resistant starch prepared by isoamylase debranching of low amylose starch |
WO2007073187A1 (en) * | 2005-12-20 | 2007-06-28 | N.V. Nutricia | Carbohydrate composition for flat glucose response |
EP1832179A1 (en) * | 2005-12-20 | 2007-09-12 | N.V. Nutricia | Carbohydrate fraction composition and flat glucose response |
US8148350B2 (en) | 2005-12-20 | 2012-04-03 | N.V. Nutricia | Carbohydrate composition for flat glucose response |
US8691976B2 (en) | 2005-12-20 | 2014-04-08 | N.V. Nutricia | Carbohydrate composition for flat glucose response |
US9095157B2 (en) | 2006-11-09 | 2015-08-04 | Toms Gruppen A/S | Sweet confectionery products |
WO2012013975A1 (en) | 2010-07-27 | 2012-02-02 | Omniceutica Limited | Nutritional compositions |
Also Published As
Publication number | Publication date |
---|---|
GB9921336D0 (en) | 1999-11-10 |
AU7025300A (en) | 2001-04-10 |
GB2353934A (en) | 2001-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2442204C (en) | Mixtures of fructose, sucrose and lactose as a low-calorie bulk sweetener with reduced glycemic index | |
JP3242660B2 (en) | Sweetener containing concentrated bioavailable calcium source | |
JP3199742B2 (en) | Concentrated bioavailable calcium source | |
US6740350B2 (en) | Confectionery compositions containing fiber | |
US3957976A (en) | Methods for reducing cholesterol levels | |
WO2001017370A1 (en) | Nutritional compositions | |
US20040058050A1 (en) | Herbal sweetening composition | |
AU2002255882A1 (en) | Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glycemic index | |
CA2292662A1 (en) | Dietetic one-to-one sugar substitute composition for table top, baking and cooking applications | |
WO2003103415A1 (en) | Novel sweetener compositions and methods of use | |
JP2010527613A (en) | Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition | |
EP1202639B1 (en) | Method for suppressing appetite | |
TWI303992B (en) | ||
MXPA06013616A (en) | Food compositions containing creatine. | |
US7147883B1 (en) | Compositions containing at least one polyol and inulin characterized by reduced tendencies of the at least one polyol to induce acute diarrhea | |
US6905702B1 (en) | Methods for regulating blood glucose and appetite suppression in type 2 diabetics | |
AU2021249556A1 (en) | Ulcerative colitis diet, formulae, products and methods thereof | |
WO2001033976A1 (en) | Methods for regulating blood glucose and appetite suppression in type 2 diabetics | |
Clifford et al. | Sugar and sweeteners | |
CN111990630A (en) | Low-sugar syrup and preparation method thereof | |
Osberger et al. | Pure fructose and its applications in reduced-calorie foods | |
US20090196956A1 (en) | Low glycemic frozen confection | |
KR20020033336A (en) | Food composition comprising extract from Polygonatum odoratum (Mill.) Druce | |
CN1168232A (en) | Health candy made of royal jelly and pollen | |
US20240108043A1 (en) | Nonnutritive sweetener compositions, methods of manufacture and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |